Risk of cardiovascular death in patients with hepatocellular carcinoma based on the Fine-Gray model

Figure 1 Multivariable analysis of cardiovascular disease in hepatocellular carcinoma patients. HR: Hazard ratio CI: Confidential interval; DSW: Divorced, separated, and widowed; AFP: Alpha fetoprotein.

Figure 2 Fine-Gray model for predicting the 2-year, 4-year, and 6-year probabilities of cardiovascular disease death among hepatocellular carcinoma patients. CVD: Cardiovascular disease; DSW: Divorced, separated, and widowed; AFP: Alpha fetoprotein.

Figure 3 Receiver operating characteristiccurves analysis for nomogram discrimination evaluation of cardiovascular disease death prediction model in hepatocellular carcinoma patients. A: 2-year receiver operating characteristic (ROC) in training set; B: 4-year ROC in training set; C: 6-year ROC in training set; D: 2-year ROC in validation set; E: 4-year ROC in validation set; F: 6-year ROC in validation set.

Figure 4 Calibration curve for nomogram calibration evaluation of cardiovascular disease death prediction model in hepatocellular carcinoma patients. A: 2-year cardiovascular mortality (CVM) in training set; B: 4-year CVM in training set; C: 6-year CVM in training set; D: 2-year CVM in validation set; E: 4-year CVM in validation set; F: 6-year CVM in validation set.

Figure 5 Decision curve analysis curves for nomogram calibration evaluation of cardiovascular disease death prediction model in hepatocellular carcinoma patients. A: 2-year decision curve analysis (DCA) curves in training set; B: 4-year DCA curves in training set; C: 6-year DCA curves in training set; D: 2-year DCA curves in validation set; E: 4-year DCA curves in validation set; F: 6-year DCA curves in validation set; DCA: Decision curve analysis.